JP4619795B2 - ホスファターゼのインヒビター - Google Patents

ホスファターゼのインヒビター Download PDF

Info

Publication number: JP4619795B2
Authority: JP; Japan
Prior art keywords: ylmethyl; furan; dihydro; quinazolin; dioxo
Prior art date: 2002-12-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2004565845A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006514658A (ja

Inventor

ジェフリーオー．サンダース，

グレゴリーエフ．ミクニズ，

アレクサンドレジェイ．バックメルター，

ケビンダブリュー．ハント，

ジェイムスエフ．ブレイク，

ガイピー．エー．ビガーズ，

シチェンサン，

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vertex Pharmaceuticals Inc

Original Assignee

Vertex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-31

Filing date

2003-12-31

Publication date

2011-01-26

2003-12-31 Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc

2006-05-11 Publication of JP2006514658A publication Critical patent/JP2006514658A/ja

2011-01-26 Application granted granted Critical

2011-01-26 Publication of JP4619795B2 publication Critical patent/JP4619795B2/ja

2023-12-31 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

0 *C(C([N+]([O-])=O)=C1)=CCC1N Chemical compound *C(C([N+]([O-])=O)=C1)=CCC1N 0.000 description 4
SACBJFFVRFQBOI-UHFFFAOYSA-N CC(N(CC1)CCC1C(NCc([nH]c1c2)cc1ccc2OC(C(O)=O)C(O)=O)=O)=O Chemical compound CC(N(CC1)CCC1C(NCc([nH]c1c2)cc1ccc2OC(C(O)=O)C(O)=O)=O)=O SACBJFFVRFQBOI-UHFFFAOYSA-N 0.000 description 1
VJNDLTGWCVAXFM-UHFFFAOYSA-N CC(Nc(cc1)ccc1S(C(Cc([nH]c1c2)cc1ccc2OC(C1CC1)C(O)=O)=N)(=O)=O)=O Chemical compound CC(Nc(cc1)ccc1S(C(Cc([nH]c1c2)cc1ccc2OC(C1CC1)C(O)=O)=N)(=O)=O)=O VJNDLTGWCVAXFM-UHFFFAOYSA-N 0.000 description 1
GPAWPFQIOHKCID-UHFFFAOYSA-N Cc1ccc(CN(C2C(C(N3C(CC(O)=O)C(O)=O)=O)=CC(Cl)=CC2)C3=O)[o]1 Chemical compound Cc1ccc(CN(C2C(C(N3C(CC(O)=O)C(O)=O)=O)=CC(Cl)=CC2)C3=O)[o]1 GPAWPFQIOHKCID-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Obesity (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Materials For Medical Uses (AREA)

JP2004565845A 2002-12-31 2003-12-31 ホスファターゼのインヒビター Expired - Fee Related JP4619795B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43757602P	2002-12-31	2002-12-31
PCT/US2003/041661 WO2004060878A2 (fr)	2002-12-31	2003-12-31	Inhibiteurs de phosphatases

Publications (2)

Publication Number	Publication Date
JP2006514658A JP2006514658A (ja)	2006-05-11
JP4619795B2 true JP4619795B2 (ja)	2011-01-26

Family

ID=32713207

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2004565845A Expired - Fee Related JP4619795B2 (ja)	2002-12-31	2003-12-31	ホスファターゼのインヒビター

Country Status (5)

Country	Link
EP (1)	EP1583747A2 (fr)
JP (1)	JP4619795B2 (fr)
AU (1)	AU2003300114B9 (fr)
CA (1)	CA2511925C (fr)
WO (1)	WO2004060878A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7713964B2 (en)	2001-12-03	2010-05-11	Wyeth Llc	Methods for treating asthmatic conditions
US7605156B2 (en)	2001-12-03	2009-10-20	Wyeth	Methods for the use of inhibitors of cytosolic phospholipase A2
TW200718687A (en)	2005-05-27	2007-05-16	Wyeth Corp	Inhibitors of cytosolic phospholipase A2
US20100113391A1 (en)	2007-04-19	2010-05-06	Astellas Pharma Inc.	Bicyclic heterocyclic compound
FR2985258A1 (fr) *	2011-12-28	2013-07-05	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
WO2015003094A2 (fr)	2013-07-03	2015-01-08	Indiana University Research & Technology Corporation	Inhibiteurs de shp2 et méthodes de traitement de maladies auto-immunes et associées à la glomérulonéphrite à l'aide d'inhibiteurs de shp2
EP3801613A1 (fr) *	2018-06-04	2021-04-14	Bayer Aktiengesellschaft	Inhibiteurs de shp2
CN111265529B (zh) *	2020-02-22	2021-07-23	南京大学	蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用
CN111333628B (zh) *	2020-04-20	2022-05-10	大连医科大学附属第一医院	吲哚类生物碱、制备方法及作为降血糖药物的应用
TW202319056A (zh) *	2021-07-09	2023-05-16	南韓商治納輔醫藥科技有限公司	Ｓｈｐ２抑制劑及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0747582B2 (ja) *	1989-12-11	1995-05-24	杏林製薬株式会社	キナゾリン―３―アルカン酸誘導体とその塩およびその製造法
DE4341665A1 (de) *	1993-12-07	1995-06-08	Basf Ag	Bicyclen-Derivate, ihre Herstellung und Verwendung
US6080772A (en) *	1995-06-07	2000-06-27	Sugen, Inc.	Thiazole compounds and methods of modulating signal transduction
WO1998018781A2 (fr) *	1996-10-28	1998-05-07	Versicor, Inc.	Banques combinatoires de 2,4-pyrimidinediones fusionnes et 2,4-pyrimidinediones fusionnes actifs biologiquement
DE19724983A1 (de) *	1997-06-13	1998-12-17	Basf Ag	Verfahren zur Herstellung von Chinazolindionen an fester Phase und ihre Verwendung
AU5826100A (en) *	1999-07-13	2001-01-30	F. Hoffmann-La Roche Ag	Benzazepinones and quinazolines
GB0022079D0 (en) *	2000-09-08	2000-10-25	Inst Of Molecul & Cell Biology	Novel protein tyrosine phosphatase inhibitor
PA8539401A1 (es) *	2001-02-14	2002-10-28	Warner Lambert Co	Quinazolinas como inhibidores de mmp-13

2003
- 2003-12-31 CA CA2511925A patent/CA2511925C/fr not_active Expired - Fee Related
- 2003-12-31 EP EP03800372A patent/EP1583747A2/fr not_active Withdrawn
- 2003-12-31 JP JP2004565845A patent/JP4619795B2/ja not_active Expired - Fee Related
- 2003-12-31 WO PCT/US2003/041661 patent/WO2004060878A2/fr not_active Ceased
- 2003-12-31 AU AU2003300114A patent/AU2003300114B9/en not_active Ceased

Also Published As

Publication number	Publication date
CA2511925A1 (fr)	2004-07-22
WO2004060878A3 (fr)	2005-01-27
JP2006514658A (ja)	2006-05-11
AU2003300114B2 (en)	2009-07-23
CA2511925C (fr)	2012-11-13
EP1583747A2 (fr)	2005-10-12
AU2003300114A1 (en)	2004-07-29
AU2003300114B9 (en)	2009-11-26
WO2004060878A2 (fr)	2004-07-22

Legal Events

Date	Code	Title	Description
2006-12-06	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061205
2010-05-14	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100513
2010-08-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100812
2010-10-12	TRDD	Decision of grant or rejection written
2010-10-15	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101014
2010-10-21	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2010-11-04	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101027
2010-11-05	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20131105 Year of fee payment: 3
2010-11-05	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2014-11-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-11-05	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP5526020B2 (ja)	2014-06-18	複素環化合物およびその使用
JP5642973B2 (ja)	2014-12-17	Ｊａｋ阻害薬として有用なｎ−複素環式化合物
TWI426908B (zh)	2014-02-21	特定化學品、組成物及方法
AU2004283139A1 (en)	2005-05-06	Compounds having CRTH2 antagonist activity
WO1999000359A1 (fr)	1999-01-07	Derives de noyau aromatique
JP2018024713A (ja)	2018-02-15	上皮成長因子受容体キナーゼ阻害剤の固体形態
CZ256795A3 (en)	1996-04-17	Derivatives of cycloalkanoindole and cyclalkanoazaindole, process of their preparation, pharmaceutical compositions containing thereof and their use
MX2007016319A (es)	2008-03-10	Derivados de n-(piridin-2-il)-sulfonamida.
CA2656716A1 (fr)	2008-01-31	Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TW200410675A (en)	2004-07-01	An NF-κB activation inhibitor
JP4619795B2 (ja)	2011-01-26	ホスファターゼのインヒビター
BG62089B1 (bg)	1999-02-26	Инхибитори на hiv реверсивна транскриптаза
WO2021078135A1 (fr)	2021-04-29	Composé pyrrole amide et son utilisation
CN105263924B (zh)	2018-10-19	Cxcr7受体调节剂
US20090060968A1 (en)	2009-03-05	Inhibitors of phosphatases
CN1938023A (zh)	2007-03-28	离子通道调节剂
WO2022083703A1 (fr)	2022-04-28	Composés et compositions pour traiter des états pathologiques associés à l'activité du récepteur lpa
JP2023518262A (ja)	2023-04-28	Ｐｈｄ阻害剤化合物、組成物、及び使用
WO2004058772A1 (fr)	2004-07-15	Derives dihydrothienoquinoline et inhibiteurs d'adhesion contenant ces derniers
DE60113248T2 (de)	2006-06-29	Vitronektin rezeptor antagonisten
JP2006502168A (ja)	2006-01-19	イソオキサゾールおよびその使用
CN1938281A (zh)	2007-03-28	离子通道调节剂
JPH10175970A (ja)	1998-06-30	ベンゾチオフェン誘導体およびそれを有効成分として含有する医薬品
CN101198605A (zh)	2008-06-11	N-(吡啶-2-基)-磺酰胺衍生物
US20230339851A1 (en)	2023-10-26	Cxcr6 sulfonamide compounds